Pyxis Oncology Q2 2026: Cash Runway to Q2 2027, Going Concern Remains
PYXS has more than doubled off its 52-week low of $1.
Summary
Pyxis Oncology's Q2 2026 10-Q shows a $25.3M quarterly loss, a cash runway into Q2 2027 after a $50M private placement, and a continued going concern warning.
Key Events · Earnings and Guidance · PYXS
-
Q2 Net Loss Widens
Net loss of $25.3 million for Q2 2026, up from $18.4 million in Q2 2025. Six-month loss of $48.6 million versus $39.5 million a year ago.
-
Cash Runway to Q2 2027
Cash, equivalents, and marketable securities of $33.0 million at June 30, 2026, plus $50 million gross from the July 2 private placement, funds operations into Q2 2027.
-
Going Concern Warning Reiterated
Management states substantial doubt about continuing as a going concern for 12 months from issuance, even after the private placement.
-
Private Placement Terms
19,600,153 shares at $2.551 per share, plus warrants for an equal number of shares at $3.289 exercise price. Up to $64 million additional if warrants are fully exercised.
Analysis · PYXS · Life Sciences
A net loss of $25.3 million for the second quarter pushed the six-month deficit to $48.6 million. The company extended its cash runway into Q2 2027 following a $50 million private placement, but management still states substantial doubt about its ability to continue as a going concern beyond 12 months. The filing also reveals the termination of the Biosion license for PYX-106 and a separation agreement with the former CEO.
At the time of this filing, PYXS was trading at $3.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $201.5M. The 52-week trading range was $1.00 to $5.55. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.